rituximab,acalabrutinib
astrazeneca
['rituximab', 'lymsm', 'cml', 'ritux']
next at #17icml mcl: frontline acala + rituximab in older adults
- 50 pts (28% tp53mut)
- orr 92% (cr 92%, mrd- 60%) at 12 wks
- time to best response = 3 wks
- 2-yr pfs 92% (!!!)
- low rates of afib (altho 'cardio-onc' clearance req)
#lymsm thinks about upfront btk all the time! 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈